Search Results (286)

A modular synthetic route has been developed to prepare a new series of cationic ruthenium(II) complexes with electron-withdrawing 1,2-diacylcyclopentadienyl ligands. The 2-acyl-6-hydroxyfulvenes were synthesized from cyclopentadienide and acyl chlorides and converted to Tl(I) cyclopentadienyl salts using Tl₂SO₄/KOH. Transmetalation with [Ru(η⁶-p-cymene)(μ-Cl)Cl]₂ followed by PF₆⁻ metathesis gives the complexes [Ru{η⁵-1,2-C₅H₃(CO–R)₂}(η⁶-p-cymene)][PF₆] (R = t-Bu, p-Tol, p-ClC₆H₄, p-IC₆H₄) in moderate to high yields. The new compounds were characterized by NMR and IR spectroscopy; mass spectrometry and elemental analysis were performed where applicable. X-ray analysis of one of the complexes confirms that electron-deficient Cp ligands retain η⁵-coordination and structural planarity within Ru(II)–arene sandwich architectures, highlighting their potential utility in electronically tunable organometallic frameworks. Full article

Cobalt–ruthenium bypiridine–oxalate metal–organic frameworks (MOFs) were synthesized via a solvothermal method with a custom-designed reactor that permits stirring, which can result in changes in the morphology of the structures. In this work, we performed a morphological and structural study of MOFs with varying tris(2,2,bipyridyl) and diclororuthenium(II) hexahydrate ${\left(Ru\right(bpy)}_3^{2+})$ concentrations, demonstrating changes in the size of the MOFs, and these MOFs were used as the luminescent materials in an electrochemiluminescent (ECL) system for glyphosate (Gly) detection, which acts as a coreactant in the light emission of ${Ru\left(bpy\right)}_3^{2+}$. Gly is the most commonly used herbicide worldwide, and our system has a calibration curve range of 10–70 ppm, with a detection limit of 7.6 ppm. Full article

The complexes cis-[Ru(dmbpy)₂Cl(bpy)](PF₆) (Rubpy) and cis-[Ru(dmbpy)₂Cl(bpe)](PF₆) (Rubpe) (dmbpy = 4,4′-Dimethyl-2,2′-dipyridyl, bpy= 4,4′-dipyridyl and bpe = 1,2-bis(4-pyridyl)ethane) were synthesized and spectroelectrochemically characterized. Both Ru(II) complexes exhibited absorption bands assigned to intraligand and metal-to-ligand charge transfer (MLCT) transitions, and their spectral stability in PBS buffer (pH 7.4) supports their suitability for biological studies involving biomolecules or living cells. Fluorescence quenching assays revealed strong interactions with bovine serum albumin (BSA), with binding constants (K_b) values were 2.89 × 10⁵ M⁻¹ for Rubpy and 1.97 × 10⁵ M⁻¹ for Rubpe, and a stoichiometry of one binding site per albumin molecule. DNA-binding studies demonstrated non-covalent interactions with ss-DNA, evidenced by a hyperchromic effect in the MLCT bands, suggesting a partial intercalation or groove-binding mechanism. Cellular uptake assays indicated moderate incorporation of both complexes in tumor cells, with uptake levels of 52% (Rubpy) and 47% (Rubpe) in HeLa cells, and 42% (Rubpy) and 32% (Rubpe) in MDA-MB-231 cells. Despite the similar uptake profiles, cytotoxicity assays showed that Rubpe is approximately 2.4 times more potent than Rubpy, with IC₅₀ values of 9 μM (HeLa) and 12 μM (MDA-MB-231), compared to 22 μM and 29 μM for Rubpy, respectively. These results highlight the relevance of these Ru(II) complexes as molecular platforms for exploring structure–activity relationships in anticancer agents. Full article

The use of metal-based species bearing existing pharmaceuticals as ligands—often resulting in enhanced bioactivity—represents an attractive strategy for the development of novel therapeutic formulations. In this context, five well-known non-steroidal anti-inflammatory drugs (NSAIDs) were employed to substitute both PPh₃ and hydride ligands in [Ru(H)₂(CO)(PPh₃)₃] (1), thereby selectively affording neutral κ²-(O,O)–chelate complexes in satisfactory yields via molecular hydrogen release. Among the obtained species, two complexes coordinating diclofenac (4) and aspirin (5) were further investigated by single-crystal X-ray diffraction (SCXRD). Preliminary biological studies were conducted on the ruthenium–salicylic acid species 2 and ibuprofen 6. The former showed promising antiproliferative activity against HeLa cancer cells, consistent with the well-established role of NSAID–ruthenium(II) complexes as a platform for the development of novel anticancer metallotherapeutics. Full article

In the quest for cheap and abundant feedstocks for sustainable hydrogen production, glycerol is emerging as a cost-effective, promising liquid organic hydrogen-rich carrier (LOHC) that can be catalytically activated to produce hydrogen alongside valuable organic products. Selective catalytic acceptorless dehydrogenation of glycerol to lactate and hydrogen gas was achieved with a maximum turnover number (TON_max) of ca. 1600, using a pincer-type ruthenium(II) complex bearing a bis(aminophosphine)pyridine PN³P ligand as a homogeneous catalyst under moderate reaction conditions (24 h, 140 °C) in the presence of KOH as base. NMR experiments and DFT calculations provided insights into key steps of the catalytic process and the energetics of the proposed reaction pathway. Full article

Our previous study demonstrated that thiophene-substituted synthetic curcumin analogs possessed better antibacterial activity and stability than natural curcumin, demethoxycurcumin, or bisdemethoxycurcumin in antibacterial photodynamic therapy (aPDT). In addition, the activity of the furan-substituted analogs was weaker than that of the thiophene-substituted compounds. As oxygen, sulfur, and selenium belong to the same group in the periodic table, the antibacterial and anticancer activities of these three different elemental analogs were compared and investigated. The thiophene-substituted analog (compound 3) exhibited the most potent antibacterial activity in aPDT experiments. However, the furan-substituted analog (compound 1) exhibited the most potent anticancer activity. These results indicate that the differences in atomic radii or energy levels in these compounds produce different cell-attack results on generated free radicals. Ruthenium(II) complexes have a good reputation for use in PDT for cancer treatment. Our results show that complexation of ruthenium(II) with thiophene-substituted curcumin analogs does not enhance their antibacterial or anticancer activity. Full article

The photochemistry of transition metal complexes has been crucial for the development of many fundamental topics, as well as to pave the way for several important applications. However, in most cases, photoactive transition metal complexes involved precious metals, with luminescent ruthenium polypyridine complexes playing the dominant role. Developing photoactive species based on earth-abundant metals is highly important for fundamental and applicative reasons. Iron is one of the most abundant metals on Earth’s crust, so luminescent iron complexes are highly desired. The recent search for iron complexes with long-lived and luminescent excited states is here presented, including Fe(II) species with metal-to-ligand charge transfer (MLCT) excited states and Fe(III) species with luminescent ligand-to-metal charge transfer (LMCT) states. The excited-state equilibration approach to prolong the luminescence lifetimes of Fe(III) compounds in multichromophoric species is also discussed. This latter approach can increase the possibility of luminescent iron complexes being involved in bimolecular processes as well as in photoinduced electron and energy transfer at interfaces, which is relevant for many applications. Full article

This study describes a series of water-soluble half-sandwich ruthenium(II), rhodium(III), and iridium(III) complexes with α-diimine ligands containing substituted aromatic groups. These ligands were derived from glyoxal and 2-aminophenol (a), 4-methyl-2-aminophenol (b), 4-aminophenol (c), phenyl hydrazine (d), and 1-aminonaphthalene (e). The ruthenium(II) (1b–1e), rhodium(III) (2a–2c, 2e), and iridium(III) complexes (3a–3e) were obtained by reacting the ligands (a–e) with the corresponding dimeric precursor [(η⁶-p-cym)RuCl₂]₂ (p-cym = p-cymene) or [(η⁵-Cp*)MCl₂]₂ (Cp* = pentamethylcyclopentadienyl, M = Rh, Ir) in air and under nonanhydro conditions. The air-stable and water-soluble ruthenium(II), rhodium(III), and iridium(III) complexes were characterized via nuclear magnetic resonance spectroscopy and electrospray ionization–mass spectrometry. The structures of complexes [(η⁶-p-cym)Ru(d)Cl]Cl, 1d; [(η⁵-Cp*)Ir(a)Cl]Cl, 3a; and [(η⁵-Cp*)Ir(c)Cl]Cl, 3c were determined via single-crystal X-ray diffraction. Additionally, the complexes exhibited catalytic activity as precatalysts in formic acid decomposition. Complex [(η⁵-Cp*)Ir(d)Cl]Cl, 3d achieved turnover number (TON) and turnover frequency (TOF) values of up to 2150 and 3861 h⁻¹, respectively, at short reaction times. In the hydrogenation of carbon dioxide, [(η⁶-p-cym)Ru(e)Cl]Cl, 1e attained TON and TOF values of up to 1385 and 69.25 h⁻¹, respectively. Full article

Photoactivatable nitric oxide donors (photoNORMs) are promising agents for controlled NO release and real-time optical tracking in biomedical theranostics. Here, we report a comprehensive density functional theory (DFT) and time-dependent DFT (TDDFT) study on a series of hybrid ruthenium–gold nanocluster systems of the general formula [(L)Ru(NO)(SH)@Au₂₀], where L = salen, bpb, porphyrin, or phthalocyanine. Structural and bonding analyses reveal that the Ru–NO bond maintains a formal {RuNO}⁶ configuration with pronounced Ru → π*(NO) backbonding, leading to partial reduction of the NO ligand and an elongated N–O bond. Natural Bond Orbital (NBO), Natural Energy Decomposition Analysis (NEDA), and Extended Transition State–Natural Orbitals for Chemical Valence (ETS–NOCV) analyses confirm that Ru–NO bonding is dominated by charge-transfer and polarization components, while Ru–S and Au–S linkages exhibit a delocalized, donor–acceptor character coupling the molecular chromophore with the metallic cluster. TDDFT results reproduce visible–near-infrared (NIR) absorption features arising from mixed metal-to-ligand and cluster-mediated charge-transfer transitions. The calculated zero–zero transition and reorganization energies predict NIR-II emission (1.8–3.8 μm), a region of high biomedical transparency, making these systems ideal candidates for luminescence-based NO sensing and therapy. This study establishes fundamental design principles for next-generation Ru-based photoNORMs integrated with plasmonic gold nanoclusters, highlighting their potential as multifunctional, optically trackable theranostic platforms. Full article

This review paper presents a comprehensive literature analysis that elucidates the global engagement of research teams in addressing the important problem of finding effective oncology drugs based on the following platinum group metal ions: ruthenium, rhodium and iridium. The necessity to search for new drugs can be attributed, in part, to the predominance of platinum-based chemotherapeutics in clinical practice. However, these drugs face limitations in their clinical application due to their inherent toxicity and the development of resistance by cancer cells. A distinctive attribute of these metal compounds is the formation of diamagnetic stable complexes on +II (Ru) and +III (Rh, Ir) oxidation degrees with a d⁶ electron configuration, a coordination number of six and an octahedral or pseudo-octahedral structure. In this paper we have systematised the findings presented in the literature by classifying the most significant categories of ruthenium, rhodium and iridium compounds, namely piano-stool-type arenes, polypyridine and cyclometalated complexes, dimers and multinuclear complexes. Additionally, the most crucial research challenges connected with metal complexes that have been addressed by scientists have been presented: (i) the application of prodrugs in cancer therapy; (ii) the deployment of complexes as sensitizers in PDT and PACT; (iii) the exploration of complexes as inhibitors of enzymes and biocatalysts; and (iv) the investigation of multiple-target complexes. Furthermore, the objective was to emphasise the accomplishments in this domain in recent years by identifying compounds that have entered the clinical trial phase. Full article

The photocatalytic reduction of carbon dioxide (CO₂) into energy-dense fuels using visible light provides a sustainable approach for solar-to-chemical energy transformation. Among the diverse metal molecular systems developed, ruthenium (II) (Ru(II)) complexes have emerged as promising catalysts due to their superior redox properties, strong visible light absorption, and customizable ligand structures. This review explores recent advances in Ru(II)-catalyzed CO₂ photoreduction, with particular attention given to catalyst design strategies, mechanistic pathways, and system integration methodologies. Key configurations, including photosensitizer/catalyst (PS/Cat) mixed systems, covalently bonded dyads, and hybrid/supramolecular frameworks, are evaluated in terms of efficiency, turnover numbers (TON), and selectivity. A critical analysis of challenges such as competing H₂ generation, inefficient charge transfer, and limited long-term stability is presented. Emerging trends toward the use of pincer ligands, transition metal integration, and self-photosensitizing frameworks are discussed as potential approaches for improving efficiency. Overall, this review offers insights into the structural and mechanistic features driving CO₂ photoreduction and provides perspectives for the rational design of next-generation Ru-based photocatalytic systems for efficient solar CO₂ conversion and the photocatalytic reduction of carbon dioxide (CO₂) into energy-dense fuels using visible light. Full article

To date, breast cancer remains one of the leading causes of death among women worldwide. Although various treatments are used in clinical settings, the efficacy and safety of such treatments are limited by tumor biology factors and patient preferences. Previous studies have shown that triple-negative BRCA1-deficient breast cancer is susceptible to DNA-damaging agents, including platinum-based drugs and poly(ADP-ribose) polymerase (PARP) inhibitors, alone or in combination. To address whether the combinative treatment of these DNA-damaging agents can be extended to the triple-negative BRCA1-proficient breast cancer population, we investigated the anticancer activity of the well-known FDA-approved PARP inhibitor olaparib in combination with the antimetastatic ruthenium(II)–arene PTA compound RAPTA-T for triple-negative BRCA1-competent breast cancer cells (MDA-MB-468 and MDA-MB-231), with consideration of sporadic breast cancer MCF-7 cells. RAPTA-T, olaparib, and the combined agents exhibited a dose-dependent inhibition of breast cancer cell growth in selected breast cancer cells. The combination compound inhibited colony formation most effectively in MDA-MB-468 cells. Additionally, the scratch-wound assay showed that MDA-MB-468 cells migrated more slowly than MCF-7 and MDA-MB-231 cells. The results indicated that the olaparib and RAPTA-T combination can reduce or inhibit the survival, invasion, and metastasis of breast cancer cells. Moreover, the combined agents promoted apoptotic cell death, with a higher percentage of apoptosis observed in MDA-MB-468 cells than in MDA-MB-231 and MCF-7 cells. Olaparib and RAPTA-T also interfered with cell cycle progression, with the greatest inhibition observed in the S and G2/M phases of MCF-7 cells (1.6- and 3.4-fold), followed by MDA-MB-468 cells (1.6- and 1.8-fold) and MDA-MB-231 cells (1.5- and 1.4-fold). Interestingly, MDA-MB-468 cells presented the highest degree of inhibition for BRCA1 replication and BRCA1 expression. The p53, PARP, and Chk1 proteins were more strongly upregulated in MDA-MB-231 cells than in Ru-untreated control cells. Moreover, the expression levels of protein biomarkers associated with the epithelial-to-mesenchymal transition (EMT), including E-cadherin and SLUG, were remarkably reduced in all tested breast cancer cells. Together, our results show the feasibility of extending the application of PARP inhibitors beyond breast cancer with BRCA1 mutations and optimizing the combinative treatment of PARP inhibitors with antimetastasis ruthenium-based chemotherapy as new therapeutic approaches for TNBC harboring wild-type BRCA1. Full article

The significant side effects associated with platinum-based anticancer agents have driven the continuous pursuit of novel, non-platinum-based metal compounds. Ruthenium-based organometallic compounds have emerged as promising alternatives, owing to their distinctive and adaptable biochemical properties. The research efforts are focused on the development of ruthenacarborane-based anticancer drugs. The combination of ruthenium(II) complexes, recognized for their inherent anticancer potential, with carboranes, boron-rich clusters possessing unique chemical and physical characteristics, and NSAIDs, known to inhibit COX, an enzyme overexpressed in tumors, offers a novel approach for cancer therapy. Consequently, combining these three moieties into a single molecule represents a compelling strategy to develop drugs with a dual mode of action. Herein, we report the synthesis of a series of ruthenacarborane-(η⁶-p-cymene)–NSAID conjugates (4a, 4b, 5b, and 6b) by linking NSAIDs (flurbiprofen, fenoprofen, and ibuprofen) to ruthenacarborane complexes using methylene and ethylene spacers, while maintaining the integrity of the sensitive ester groups present in the system. The synthesized conjugates were thoroughly characterized using multinuclear (¹H, ¹¹B, and ¹³C) NMR spectroscopy. Notably, the conjugates demonstrated low COX inhibition and no cytotoxic potential against different cancer cell lines, probably due to oxidative deactivation confirmed by cyclic voltammetry (CV). This indicates that the conjugation of this type of ruthenacarborane with NSAIDs does not result in novel anticancer drugs. Full article

Electrogenerated chemiluminescence (ECL) is a powerful analytical technique that combines the best features of both electrochemical and photoluminescence methods. In this work, we present a direct ECL-based method for the detection of fentanyl using unmodified screen-printed electrodes. The analysed system consists of tris(2,2′-bipyridyl)ruthenium(II) (Ru(bpy)₃²⁺) as the luminophore and fentanyl as the co-reactant. A comprehensive optimization of the experimental parameters, such as buffer pH, luminophore concentration and working electrode material, was performed in order to maximize the ECL response. The optimal conditions are identified as PBS buffer pH 6, 2.5 × 10⁻³ M Ru(bpy)₃²⁺ and bare gold screen-printed electrodes. Under these conditions, the system exhibited a strong and reproducible ECL signal, with a linear response to fentanyl concentration from 1 × 10⁻⁷ to 1 × 10⁻⁵ M and a limit of detection of 6.7 × 10⁻⁸ M. Notably, the proposed method does not require electrode surface modification, sample pretreatment or complex instrumentation, offering a rapid, sensitive, and cost-effective alternative for fentanyl detection. Furthermore, the storage of bare SPEs at room temperature in a dry place ensures their stability over months or even years, overcoming the limitations offered by ECL systems based on modifications of the working electrode with different nanomaterials. These findings highlight the potential of the proposed ECL approach as a robust and sensitive tool for the detection of synthetic opioids. Its simplicity, portability, and analytical performance make it particularly attractive for forensic and clinical applications where rapid and accurate opioid screening is essential. Full article

Background/Objectives: Colorectal carcinoma (CRC) is among the most commonly diagnosed cancers in both men and women. Although CRC mortality is generally decreasing, new therapeutic options are needed for unresponsive subgroups of CRC patients. Methods: A series of known and new tyrphostin derivatives was tested for their efficacy against three CRC cell lines with varying KRAS, p53, and/or BRAF statuses. Growth inhibition, apoptosis induction, and inhibition of EGFR and VEGFR-2 were investigated. Results: Tyrphostin A9, the known RG13022-related tyrphostin 1a and its dichlorido(p-cymene)ruthenium(II) complex 1b, and the new SF₅-substituted compounds 2a and 2b showed selective antiproliferative activity against KRAS-mutant HCT-116 CRC cells expressing wildtype p53, while p53-knockout HCT-116 and KRAS-wildtype BRAF/p53-mutant HT-29 CRC cells were distinctly less sensitive. In HCT-116 cells, only tyrphostin A9 increased mRNA expression of caspases 3 and 8, as well as the kinases MEK1 and MEK2, whereas 2a reduced caspase 8 mRNA levels. Tyrphostin A9 increased caspase 3 activity and induced apoptosis in HCT-116 p53-wildtype cells while simultaneously inhibiting the receptor tyrosine kinases EGFR and VEGFR-2 at low nanomolar concentrations. Conclusions: Tyrphostin A9 could be a promising therapeutic option for the treatment of KRAS-mutant CRC that expresses wildtype p53. Full article